Ventoxen (Venetoclax), the generic form of Venclexta, is a prescription medication used to treat adult patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML). Venetoclax works by slowing down or stopping the growth of cancer cells.

This medication is manufactured by Everest Pharma Ltd. in Bangladesh.

Administration Instructions:

Ventoxen should be taken orally once daily with a meal and water, at approximately the same time each day.

Side Effects:

The most common adverse reactions associated with Ventoxen include:

• Diarrhea
• Nausea
• Vomiting
• Tiredness
• Headache

Please note that the information provided is sourced from the internet. It is essential to consult with a doctor for personalized medical advice.

Disclaimer:

• Any advice on the use of this medication is for reference purposes only. Consult with a healthcare professional for personalized medical advice. All names, logos, and trademarks are the property of their respective owners. Watermarks and QR codes are used for identification purposes only.

The post Ventoxen 100mg (Venetoclax) appeared first on BD Anticancer Drug Supplier.

Brand: Incepta Pharmaceuticals

Mantle Cell Lymphoma: Ibrutinib is indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia.

Waldenstrom Macroglobulinemia (WM): Ibrutinib is indicated for the treatment of patients with Waldenstrom Macroglobulinemia (WM).

Marginal Zone Lymphoma: Ibrutinib is indicated for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD 20-based therapy.

• Take according to the doctor’s advice
• Therapeutic Class
• Targeted Cancer Therapy
• Pharmacology

Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in the activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Dosage
Mantle Cell Lymphoma and Marginal Zone Lymphoma: The recommended dose of Ibrutinib for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM): The recommended dose of Ibrutinib for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity. The recommended dose of Ibrutinib for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
*Take according to the doctor’s advice
Administration
Administer Ibrutinib orally once daily at approximately the same time each day.
Swallow the capsules whole with water. Do not open, break, or chew the capsules.
*Take according to the doctor’s advice
Interaction
CYP3A Inhibitors: Co-administration with strong and moderate CYP3A inhibitors should be avoided. If a moderate CYP3A inhibitor must be used, Ibrutinib dose should be reduced

CYP3A Inducers: Co-administration with strong CYP3A inducers should be avoided
Contraindications
Hypersensitivity to the active substance or to any of the excipients.

Side Effects
The following adverse reactions are discussed in more detail in other sections of the labeling: Hemorrhage, Infections, Cytopenias, Atrial Fibrillation, Hypertension, Second Primary Malignancies and Tumor Lysis Syndrome. Additional Important Adverse Reactions: Diarrhea, Visual Disturbance.

Pregnancy & Lactation

Pregnancy: Ibrutinib, a kinase inhibitor, can cause fetal harm based on findings from animal studies. In animal reproduction studies, administration of Ibrutinib to pregnant rats and rabbits during the period of organogenesis at exposures up to 2-20 times the clinical doses of 420-560 mg daily produced embryofetal toxicity including malformations. If Ibrutinib is used during pregnancy or if the patient becomes pregnant while taking Ibrutinib, the patient should be apprised of the potential hazard to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Lactation: There is no information regarding the presence of Ibrutinib or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.

Overdose Effects

There is no specific experience in the management of Ibrutinib overdose in patients. One healthy subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 1680 mg. Closely monitor patients who ingest more than the recommended dosage and provide appropriate supportive treatment.

Use in Special Population
Pediatric Use: The safety and effectiveness of Ibrutinib in pediatric patients has not been established.

Geriatric Use: Of the 905 patients in clinical studies of Ibrutinib, 62% were ≥ 65 years of age, while 21% were ≥75 years of age. No overall differences in effectiveness were observed between younger and older patients. Anemia (all grades) and Grade 3 or higher pneumonia occurred more frequently among older patients treated with Ibrutinib.

Hepatic Impairment: Ibrutinib is metabolized in the liver. In a hepatic impairment study, data showed an increase in Ibrutinib exposure. The safety of Ibrutinib has not been evaluated in cancer patients with mild to severe hepatic impairment by the Child-Pugh criteria. Monitor patients for signs of Ibrutinib toxicity and follow dose modification guidance as needed. It is not recommended to administer Ibrutinib to patients with moderate or severe hepatic impairment.
Storage Conditions
Store in a dry place below 30°C, and protect from light. Keep out of the reach of children.

The post Ibrucent 140 Mg (Ibrutinib) appeared first on BD Anticancer Drug Supplier.

Ponaxen active ingredient Ponatinib a Generix of ICLUSIG / ICLUSIG 45mg is used to treat leukemia.

Ponaxen is distributed and manufactured by Everest Pharmaceutical Company Bangladesh.

Ponaxen is used to:

Chronic myeloid leukemia (CML) in its different stages are called chronic, accelerated and blast phase;

Acute lymphoblastic leukemia (ALL) in Philadelphia-chromosome-positive (Ph+) patients.

Ph+ means that some of the patient’s genes have rearranged themselves. This forms a special chromosome called the Philadelphia chromosome that develops white blood cells.

Ponxen is used in patients who cannot use:

• Dasatinib (patients with CML or ALL).
• Nilotinib (patients with CML).
• Other cancer drugs of the same type and treated with imatinib

Ponaxen is also used in patients who have a mutation in a gene called ‘T315I mutation. This mutation makes them resistant to treatment with imatinib, dasatinib, or nilotinib.

Ingredient

Active ingredients: Ponatinib 15mg, 30mg, 45mg.

Specification: Box of 30 tablets.

Origin: Bangladesh.

What does Ponaxen do?

Ponaxen Active ingredient Ponatinib is a kinase inhibitor. Ponatinib inhibits the in vitro tyrosine kinase activity of ABL and ABL mutant T315I with IC50 concentrations of 0.4 and 2.0 nM, respectively.

Ponatinib inhibits the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM. Includes members of VEGFR, PDGFR, FGFR, EPH receptor and SRC kinase families, and KIT, RET, TIE2, and FLT3.

Ponatinib inhibits the in vitro viability of wild-type or mutant BCR-ABL-expressing cells including T315I.

In mice, ponatinib treatment reduced the size of tumors expressing mutant BCR-ABL or mutant T315I when compared with controls.

Dosage and use of Ponaxen

Ponaxen is prescribed and prescribed by a doctor.

Ponaxen is available as a tablet (15 mg, 30 mg and 45 mg). The recommended starting dose is 45 mg once daily.

Treatment is continued as long as the patient benefits.

If a patient develops certain serious side effects. Your doctor may decide to reduce your next dose or delay or stop treatment.

The doctor should consider stopping treatment if the level of white blood cells in the blood does not return to normal within three months.

Ponaxen may lead to blood clots or blockages in arteries and veins and patients should have their heart and circulatory status reviewed before initiating and during treatment, and receive appropriate treatment for any problems. which topic.

Dosage reduction or interruption may be necessary if the patient experiences certain side effects; It should be interrupted immediately if a blockage develops in an artery or vein.

The post Ponaxen 15mg & 45mg (Ponatinib) appeared first on BD Anticancer Drug Supplier.